These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 35708343)

  • 1. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
    Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
    J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
    Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
    He H; Wen X; Zheng H
    Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of gilteritinib for relapsed/refractory
    Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
    Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
    Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
    Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
    Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
    Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
    Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
    Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
    Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
    N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
    J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
    Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
    J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
    Pratz KW; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Döhner H; Récher C; Fiedler W; Yamamoto K; Wang J; Yoon SS; Wolach O; Yeh SP; Leber B; Esteve J; Mayer J; Porkka K; Illés Á; Lemoli RM; Turgut M; Ku G; Miller C; Zhou Y; Zhang M; Chyla B; Potluri J; DiNardo CD
    Am J Hematol; 2024 Apr; 99(4):615-624. PubMed ID: 38343151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
    Qin Y; Kuang P; Liu T
    Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
    Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
    Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.